公开(公告)号：US20160296548A1

公开(公告)日：2016-10-13

申请号：US15036544

申请日：2014-11-13

Applicant: EPIZYME, INC.

Inventor： Roy M. Pollock ,  Scott R. Daigle ,  Eric Hedrick ,  Nigel Waters ,  Blythe Thomson

IPC: A61K31/7076

CPC classification number: A61K31/7076 ,  C07H19/16

Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Abstract translation: 本发明涉及DOT1L抑制剂。 本发明还涉及含有这些化合物的药物组合物和通过将这些化合物和药物组合物施用于有需要的受试者来治疗其中DOT1介导的蛋白质甲基化部分如癌症的疾病的方法。

公开(公告)号：US10143704B2

公开(公告)日：2018-12-04

申请号：US15036544

申请日：2014-11-13

Applicant: Epizyme, Inc.

Inventor： Roy M. Pollock ,  Scott R. Daigle ,  Eric Hedrick ,  Nigel Waters ,  Blythe Thomson

IPC: A61K31/7076 ,  C07H19/16

Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.